The share

Chordate has only one class of shares and all shares have equal rights to dividend and surplus upon liquidation and one vote at the general meeting. Shareholders in the company have preferential rights when shares are issued, in proportion to existing holdings.

Chordate's shares have been issued in accordance with Swedish law and are denominated in SEK. The company's shares are registered with Euroclear in electronic form and Euroclear also keeps the company's share book.

Trading of shares

The company's shares have been traded on NGM Nordic SME since March 8, 2017.

Trading information

ISIN: SE0009495559

Stock symbol: CMH

To follow the share price on NGM’s website, click here.

NGM Nordic SME

Nordic SME is a growth market for small and medium-sized enterprises (SMEs) for listing and trading in shares and share-related securities operated by Nordic Growth Market NGM AB. Nordic SME is an SME growth market for small and medium-sized enterprises in accordance with MiFID II (Markets in Financial Instruments Directive II). An investor should keep in mind that shares and share-related securities listed on Nordic SME are not listed on a regulated market and that the company is therefore not subject to the same provisions relating to protection of shareholders as companies whose shares are listed on a regulated market.

We are a Swedish medical technology company listed on NGM Nordic SME.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact